The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are:
1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC;
2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC
3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens
Participants will:
1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam.
2. Have a blood test for serum LH, oestradiol an progesterone.
3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used.
4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation.
5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of Hong Kong

[+1]

IRCT20241117063744N1

/ RecruitingPhase 3IIT

Evaluation of topical Piroxicam in prevention of Capecitabine-related hand-foot syndrome in patients with colon and breast cancer: a randomized, double-blind clinical trial study

Start Date21 Nov 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

IRCT20180526039846N2

/ CompletedPhase 3IIT

Investigation and comparison of ibuprofen and piroxicam in patients aged 20 to 50 with renal colic referred to emergency room.

Start Date20 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Piroxicam

100 Translational Medicine associated with Piroxicam

100 Patents (Medical) associated with Piroxicam

6,588

Literatures (Medical) associated with Piroxicam

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

A simple and efficient “cell in situ collagen zymography” technique to evaluate cellular collagenase activities in thyroid cancer cell lines

Article

Author: Savas, Ege Gokce ; Oktay, Gulgun ; Sipahi, Murat ; Surer, Seniz Inanc ; Keles, Didem

BACKGROUND:

Collagenases, a subgroup of matrix metalloproteinases (MMPs), play crucial roles in local invasion and metastasis in cancer. While substrate zymography and in situ zymography are commonly used to analyze the collagenases, traditional techniques have limitations in determining their local activities in vitro.

OBJECTIVES:

We aimed to develop a new "cell in situ collagen zymography" technique to enhance the efficiency of studying local collagenase activities in vitro.

METHODS:

We utilized human thyroid cancer cell lines (8505 C, B-CPAP, FTC-133) and normal follicular thyroid cell line (Nhty-ori-3-1). We compared collagenase levels across these cell lines and selected 8505 C as a model due to its highest collagenase activity. We optimized factors including (i) fixation method (methanol, ethanol and zinc), (ii) dye-quenched (DQ) collagen concentration and (iii) collagen gel configuration. For gel configuration, cells were seeded under, on the top of, or between (sandwich) collagen gel layers. As controls, enzymatic activity was suppressed in the presence of EDTA, piroxicam and matrix metalloproteinase 8 inhibitor I. The optimized method was also applied to BCPAP, FTC-133, and Nthy-ori-3-1.

RESULTS:

Our optimization process revealed that that the best visualization of collagenase activity in 8505 C was provided by the "sandwich model" of gel, containing 25 µg/mL of DQ-collagen with 100% cold methanol fixation. We confirmed the optimized method's applicability in other thyroid cell lines. The use of inhibitors validated the specificity of the fluorescent signal to MMP activity.

CONCLUSION:

The innovative "cell in situ collagen zymography" technique offers an efficient, cost-effective, and rapid method for analyzing local collagenase activities in vitro.

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Insights into salts/cocrystals formation of polyhydroxy natural products as well as their separation behavior via cocrystallization

Author: Ouyang, Jinbo ; Xu, Li ; Jerry, Heng ; Zhou, Limin ; Li, Detao ; Ning, Zichen ; Du, Shichao ; He, Feiqiang ; Gong, Zhuoshan ; Shehzad, Hamza

According to in-depth research on cocrystals of polyhydroxylated natural products, we previously summarized the substitution model to elucidate the formation mechanism of cocrystals.However, when refers to salt formation of natural products, the substitution model reveals numerous deficiencies.To compensate for the shortcomings of substitution model in predicting salt formation, this study conducts a comprehensive exploration of natural product salts.By supplementing the energy difference rule to the substitution model, it endows the modified model with broader applicability.Simultaneously, the transfer of protons within salts structures is verified by this modified model.Furthermore, we apply competitive cocrystn. technique to sep. flavonoid natural products (quercetin, hesperetin, and naringenin).In view of the characteristics of various natural products as well as their cocrystals/salts, numerous separation processes are developed, and the separation effects of these processes are analyzed in detail.The purity of the products obtained from separation process all reaches above 70%, strongly demonstrating the feasibility of using cocrystn. for the binary separation of flavonoids.This work not only refines the substitution model for predicting cocrystals/salts formation of natural products but also indicates the promising application prospects of cocrystn. in industrial separation of natural products.

01 May 2025·BIOMEDICAL CHROMATOGRAPHY

Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti‐Inflammatory Prototype 5‐[1‐(4‐Fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) Through Selective Bioanalytical HPLC‐PDA‐Based Method

Article

Author: Cruz, Alessandro Carvalho ; Fajemiroye, James Oluwagbamigbe ; da Cunha, Luiz Carlos ; Menegatti, Ricardo ; Marques, Stefanne Madalena ; Lião, Luciano Morais ; Pedrino, Gustavo ; de Oliveira, Thiago Sardinha ; de Oliveira Neto, Jerônimo Raimundo ; Naves, Lara Marques ; de Oliveira, Lanussy Porfiro

ABSTRACT:

A simple and selective high‐performance liquid chromatography bioanalytical method was developed and validated to determine the pharmacokinetic parameters of 5‐[1‐(4‐fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) with promising vasorelaxant, anti‐inflammatory, and antinociceptive properties while verifying its potential hepatic enzyme induction or inhibition. Chromatographic separation was achieved using a reversed‐phase C18 column (ACE, 150 × 4.6 mm, 5 μm) with isocratic elution of a solvent mixture comprising acetonitrile and 0.2% formic acid (30:70, v/v). Detection of LQFM020 and the internal standard, piroxicam, was performed using a photodiode array detector. The method demonstrated excellent linearity (r > 0.998), with precision and accuracy within acceptable limits [intraday precision: 6.1%, interday precision: 9.3%; intraday accuracy: 113.2%, interday accuracy: 107.3%]. Pharmacokinetic studies revealed rapid oral absorption of LQFM020 at doses of 9, 18, and 36 mg/kg, as well as following a single intravenous dose (10 mg/kg). LQFM020 exhibited an absolute bioavailability of 46%, a relatively low apparent volume of distribution, and moderate elimination rates, suggesting extensive plasma protein binding. Additionally, LQFM020 showed no significant effect on the biotransformation of compounds mediated by the cytochrome P450 CYP3A4 enzyme. In conclusion, this new bioanalytical method supports preclinical studies and provides a basis for the utility of LQFM020 as a potential drug candidate.

News (Medical) associated with Piroxicam

12 Dec 2024

·www.globenewswire.com

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesTORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation (“MUMS”) from the U.S. Food and Drug Administration (“FDA”) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The company received a notification from the FDA on December 9th 2024. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the company meets all requirements for maintaining the designation. “In a relatively short period of time, we have made remarkable progress with the FDA in advancing the clinical development program of the veterinary application of our novel D-MNA patch in treating SCC in horses,” stated Dr. Raza Bokhari, Executive Chairman & CEO. “Developing a non-invasive treatment for equine SCC represents an untapped market opportunity that we are excited to pursue. The MUMS designation is an important catalyst to provide us a first mover advantage and also position us to possibly have a commercially viable product as early as 2026.” Doxorubicin-containing microneedle array (D-MNA) is a patent protected dissovable transdermal patch with cellulose based microneedle arrays that are tip-loaded with doxorubicin. After application, the microneedles function by penetrating the strateum corneum layer of the skin, create a temporary microchannel, penetrate the tumor, dissolve and release doxorubicin into the target tumor, and eradicate the cancer cells. Squamous Cell Carcinoma (SCC) in Horses SCC is a mucocutaneous skin tumor in horses, primarily affecting adult or aged horses with white or partially white coats. Breeds like Appaloosa, Belgian, American Paint, and Pinto are particularly susceptible. SCC often develops in areas with minimal pigmentation and sparse hair, notably around mucous membranes. More specifically, tumors are mainly seen around the eyes, lips, nose, anus, and external genitalia. The overall incidence of SCC is 2-3% and recent estimates of the US horse population range from 6.6 to 7.25 million horses. Current treatment includes surgery to remove the largest mass, cryotherapy of the smaller mass, and local injection of a chemotherapy drug. In some cases, a topical chemotherapeutic drug will be prescribed in the form of drops (tumors near the eye) or cream (tumors in other parts of body). Additionally, some horses are put on an oral drug called piroxicam that may slow the return of the cancerous cells. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@medicuspharma.com Jeremy FefferLifeSci Advisors(212) 915-2568jfeffer@lifesciadvisors.com About Medicus Pharma Ltd: Medicus Pharma Ltd. (Nasdaq: MDCX, TSXV: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company submitted a Phase 2 IND clinical protocol to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two dose of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is currently underway in nine sites across the United States. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s plans and expectations concerning, and future outcomes relating to, its product development plans and clinical development programs, including improvements thereto and the timing thereof, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on SEDAR+ and on EDGAR, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Company’s long form prospectus accessible on the Company's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Orphan DrugPhase 1Phase 2

20 Oct 2023

·www.sciencedaily.com

Morning-after pill more effective when taken with an anti-inflammatory painkiller, researchers find

A research team recently published findings on adding an anti-inflammatory painkiller used for arthritis pain to an oral emergency contraceptive pill (also known as the morning-after pill) to increase the effectiveness of pregnancy prevention. A collaborative research team, including members of LKS Faculty of Medicine of the University of Hong Kong (HKUMed), as well as The Family Planning Association of Hong Kong (FPAHK) and Sweden's Karolinska Institutet, recently published its findings on adding an anti-inflammatory painkiller used for arthritis pain to an oral emergency contraceptive pill (also known as the morning-after pill) to increase the effectiveness of pregnancy prevention. The study was published in a recent issue of The Lancet. Background Emergency contraception is a contraceptive method that can be used to prevent an unintended pregnancy when a regular contraceptive method fails or is not used. It can be in the form of an oral emergency contraceptive pill or the insertion of a copper intrauterine contraceptive device (Cu-IUD). The oral levonorgestrel emergency contraceptive pill is one of the most popular choices of emergency contraception and is widely used in most countries. It was pioneered by a clinical trial in Hong Kong led by HKUMed's Professor Ho Pak-chung, published in 1993. However, all contraceptive methods have a failure rate. Hence, the research team is continuing its efforts to explore more effective options. Prostaglandins are substances produced by most body tissues in humans and mediate a number of biological processes, including inflammatory responses. In the reproductive system, prostaglandin is an important mediator of processes like ovulation, fertilisation and embryo implantation. The research team postulated that adding a medication that blocks prostaglandin synthesis may have an additional complementary effect in achieving contraception. Research methods and findings The research team conducted the first randomised, placebo-controlled trial in the world on the use of piroxicam, a long-acting nonsteroidal anti-inflammatory drug (NSAID) used to treat arthritis pain, which blocks prostaglandin production in the body, in combination with the levonorgestrel emergency contraceptive pill. The findings revealed that with the new combination regimen, only one out of 418 women became pregnant, while seven out of another 418 women receiving levonorgestrel and a placebo became pregnant. The results showed that the percentage of pregnancies prevented by piroxicam-levonorgestrel co-treatment (94.7%) was significantly higher than that of the levonorgestrel emergency contraceptive pill alone (63.4%). There was no significant difference in the occurrence of adverse effects, including changes to the menstrual bleeding pattern and stomach ache following intake of the two regimens. Significance of the study Chief-investigator Dr Raymond Li Hang-wun, from HKUMed, said, 'Our study is the first to find that piroxicam, a readily available medication, taken at the same time as the levonorgestrel pill can prevent more pregnancies than levonorgestrel alone. We hope these findings will lead to further research and ultimately changes in clinical guidelines to enable women around the world to access more effective emergency contraception.' Co-investigator Dr Sue Lo Seen-tsing, from FPAHK, said, 'The levonorgestrel pill was registered in Hong Kong in 2002 and has been used safely since then. Locally, emergency contraceptives must be prescribed by healthcare providers, who assess which emergency contraceptive method is the most suitable in each case. Contraceptive counselling should be provided to help women seeking emergency contraception understand that it cannot replace regular contraceptives and to motivate them to use the latter. Since there is still a small failure rate, a follow-up visit is important. The levonorgestrel emergency contraception pill should be taken within 72 hours after unprotected sex; the earlier it is taken, the more effective it is.' About the research team The study was led by Dr Raymond Li Hang-wun, Clinical Associate Professor in the Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed. The collaborative research team also included Professor Ho Pak-chung, Emeritus Professor, and Professor Ernest Ng Hung-yu, Clinical Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed; Carol Fong Ho-yi, Department of Medicine, School of Clinical Medicine, HKUMed; Dr Sue Lo Seen-tsing, The Family Planning Association of Hong Kong; and Professor Kristina Gemzell-Danielsson, Head, Department of Women's and Children's Health, Karolinska Institutet, Sweden. Acknowledgements This work was supported by research funding from the Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed.

Clinical ResultDrug Approval

24 Jan 2021

·www.biospace.com

Nanoform's Clinical Study Indicates Positive Interim Results - Jan 22, 2021

HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) Profile of Piroxicam following Administration of Nanoformed Oral Immediate Release (IR) Piroxicam Tablet and an IR Reference Product in Healthy Subjects (UNICORN). These interim results are based on the first cohort of twelve healthy volunteers dosed in December 2020 at Quotient Sciences' facilities in Nottingham, UK. Final results of the study are expected before the end of Q2 2021, as previously announced. This first set of human data supports Nanoform's value proposition that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery performance, and ultimately generate patient benefit. The interim results obtained from the ongoing clinical trial, suggest that a 20 mg nanoformed oral piroxicam tablet achieved significantly faster absorption when compared to a 20 mg reference oral piroxicam tablet (Felden®) from the originator Pfizer. The time of maximum plasma concentration (T max ) was obtained earlier than with the reference product. These interim results support the further development of fast-acting forms of poorly soluble drugs by using the CESS® nanoforming technology. For further information, please contact: Prof. Edward Hæggström, CEO edward.haeggstrom@nanoform.com +358 29 370 0150 For investor relations queries, please contact: Henri von Haartman, Director of Investor Relations hvh@nanoform.com +46 7686 650 11 The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on January 22nd, 2021 at 08:10 a.m. Finnish time. About Nanoform Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on May 22, 2020) in connection with Nanoform's initial public offering (the "Prospectus") under "Risk Factors" and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This information was brought to you by Cision The following files are available for download: View original content: SOURCE Nanoform

Financial StatementIPO

100 Deals associated with Piroxicam

External Link

KEGG	Wiki	ATC	Drug Bank
D00127	Piroxicam	M02AA07 M01AC01 S01BC06	DB00554

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bursitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	28 Feb 2007
Myalgia	Japan	Pfizer Japan, Inc.	25 Sep 1986
Periarthritis scapulohumeralis	Japan	Pfizer Japan, Inc.	25 Sep 1986
Tennis Elbow	Japan	Pfizer Japan, Inc.	25 Sep 1986
Tenosynovitis	Japan	Pfizer Japan, Inc.	25 Sep 1986
Wounds and Injuries	Japan	Pfizer Japan, Inc.	25 Sep 1986
Osteoarthritis	United States	Pfizer Laboratories (Pty) Ltd.	06 Apr 1982
Rheumatoid Arthritis	United States	Pfizer Laboratories (Pty) Ltd.	06 Apr 1982
Pain	China	Jiangsu Yixing Qianjin Pharmacy Factory	01 Jan 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03614494 (CTgov)	Phase 2/3	Contraception	860	Levonorgestrel+Piroxicam 40 mg (Piroxicam)	mjmcguwhak = dakqggecwt okmliaybiv (abalzpubls, kcshfnwgfs - spvqfyvczq) View more	-	06 May 2024
				Levonorgestrel (Placebo)	mjmcguwhak = mjroaaubdv okmliaybiv (abalzpubls, ewsiktzfgq - ghrbssjdnp) View more
EULAR2022	Not Applicable	Non-radiographic axial spondyloarthritis	43	Continuous NSAIDs intake	fzlvnchudw(msadzsohjv) = blqkmmsliq yuhfyfhovg (owklknfjwf ) View more	Positive	01 Jun 2022
				Occasional NSAIDs intake	fafwzyeiwf(yfrdogkkbe) = xzljpbbklj vwwlkvhpic (euyusdidnx )
NCT02450487 (CTgov)	Phase 4	Pain \| Cytochrome p450 enzyme deficiency	105	Piroxicam	vrbximfwzy(ijzxcvjsae) = simsipryfb ugerjbbefu (blwwqesimw, 25) View more	-	16 Sep 2020
ISRCTN22070974 (Pubmed \| Curr Med Res Opin)	Phase 3	Actinic Keratosis	54	ACTX	nretpolzdt(nvsbhzzwih) = hscbexrntu rebalrhohp (hqadabgjsa ) View more	-	01 Oct 2019
EULAR2008	Not Applicable	-	-	Ibuprofen	cvyakaifzz(htiwfqocaa) = uisouxfduu wdmldvlxxa (rskxtpyrkv )	-	11 Jun 2008
				Naproxen	cvyakaifzz(htiwfqocaa) = fnclxbjssu wdmldvlxxa (rskxtpyrkv )
EULAR2001	Not Applicable	-	70	Tramadol/piroxicam combination	fzmbmxqrib(vsaxlrrbni) = 18% pfqakpfafe (xacyewiwcm ) View more	-	13 Jun 2001
Pubmed	Not Applicable	Periarthritis scapulohumeralis \| Cervicobrachial syndrome	-	Piroxicam	eviznqbujm(lepclgfzqw) = Fewer adverse reactions were observed with piroxicam zbcyifzisk (acgyulduyo ) View more	-	01 Jan 1983
				Indomethacin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Piroxicam

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation